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Abstract
Background: Although new molecular diagnostic tests such as GenoType MTBDRplus and Xpert® MTB/RIF
have reduced multidrug-resistant tuberculosis (MDR-TB) treatment initiation times, patients’ experiences of
diagnosis and treatment initiation are not known. This study aimed to explore and compare MDR-TB patients’
experiences of their diagnostic and treatment initiation pathway in GenoType MTBDRplus and Xpert® MTB/
RIF-based diagnostic algorithms.
Methods: The study was undertaken in Cape Town, South Africa where primary health-care services provided
free TB diagnosis and treatment. A smear, culture and GenoType MTBDRplus diagnostic algorithm was used
in 2010, with Xpert® MTB/RIF phased in from 2011–2013. Participants diagnosed in each algorithm at four
facilities were purposively sampled, stratifying by age, gender and MDR-TB risk profiles. We conducted in-
depth qualitative interviews using a semi-structured interview guide. Through constant comparative analysis
we induced common and divergent themes related to symptom recognition, health-care access, testing for
MDR-TB and treatment initiation within and between groups. Data were triangulated with clinical information
and health visit data from a structured questionnaire.
Results: We identified both enablers and barriers to early MDR-TB diagnosis and treatment. Half the patients
had previously been treated for TB; most recognised recurring symptoms and reported early health-seeking.
Those who attributed symptoms to other causes delayed health-seeking. Perceptions of poor public sector
services were prevalent and may have contributed both to deferred health-seeking and to patient’s use of
the private sector, contributing to delays. However, once on treatment, most patients expressed satisfaction
with public sector care. Two patients in the Xpert® MTB/RIF-based algorithm exemplified its potential to
reduce delays, commencing MDR-TB treatment within a week of their first health contact. However, most
patients in both algorithms experienced substantial delays. Avoidable health system delays resulted from
providers not testing for TB at initial health contact, non-adherence to testing algorithms, results not being
available and failure to promptly recall patients with positive results.
(Continued on next page)
* Correspondence: pnaidoo@icon.co.za
1Desmond Tutu TB Centre, Department of Paediatrics and Child Health,
Faculty of Medicine and Health Sciences, Stellenbosch University,
Stellenbosch, South Africa
Full list of author information is available at the end of the article
© 2015 Naidoo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Naidoo et al. BMC Health Services Research  (2015) 15:488 
DOI 10.1186/s12913-015-1145-0
(Continued from previous page)
Conclusion: Whilst the introduction of rapid tests such as Xpert® MTB/RIF can expedite MDR-TB diagnosis
and treatment initiation, the full benefits are unlikely to be realised without reducing delays in health-seeking
and addressing the structural barriers present in the health-care system.
Keywords: GenoType MTBDRplus line probe assay, Xpert® MTB/RIF, Pathways to care, Health-seeking
behaviour, Diagnostic and treatment delay, Obstacles to care
Background
The World Health Organisation (WHO) identified the need
to address multi-drug resistant tuberculosis (MDR-TB) as a
public health crisis as one of five key priorities [1]. Improv-
ing MDR-TB control requires rapid, accurate diagnostics to
enable early and appropriate treatment [1, 2] with benefit
to both patients and the public through reductions in mor-
bidity, mortality and transmission within communities
[2, 3]. Advances have been made in the development,
evaluation and routine use of rapid, accurate molecu-
lar diagnostic tests for MDR-TB. South Africa was an
early adopter of two WHO approved tests, GenoType
MTBDRplus (Hain Lifescience GmbH, Nehren, Germany)
line probe assay (LPA) [4] and Xpert® MTB/RIF (Cepheid,
Sunnyvale, CA, USA) (Xpert) [5].
Studies have shown that both LPA [6, 7] and Xpert [8]
reduced MDR-TB diagnostic and treatment initiation
times in comparison to previous tests. Test performance,
as well as both patient and health system factors influ-
ence the potential of rapid diagnostics to reduce diag-
nostic and treatment delays [9]. Although not specific to
MDR-TB, studies have found a number of factors associ-
ated with patient delay in accessing care in sub-Saharan
Africa [10]. Fear of a positive human immunodeficiency
virus (HIV) test or the stigma associated with this [11–13],
the belief that symptoms, like cough, would resolve spon-
taneously or improve with self-medication [11, 13, 14], un-
certainty about the cause of their illness and visits to
multiple providers [13–15] all contributed to delays in
seeking care. Health provider delays were influenced by
the availability of laboratory resources, initial screen-
ing efficacy, timely and correct request for laboratory
investigations and the coordination of patient manage-
ment between different health-care providers [13, 16, 17].
There is a paucity of literature detailing MDR-TB pa-
tients’ experience of diagnosis and treatment initiation.
This study aimed to explore and compare MDR-TB pa-
tients’ experiences of their pathway to diagnosis and treat-
ment initiation in LPA and Xpert-based diagnostic
algorithms. The study was part of a broader PROVE IT
(Policy Relevant Outcomes from Validating Evidence on
ImpacT) (http://www.treattb.org) evaluation that assessed
the impact of new molecular tests on the diagnosis and
treatment of TB in routine operational conditions. Impact
analysis was guided by the Impact Assessment Framework
[18] which provides a systematic, comprehensive approach
to generating evidence to support decision-making for new
diagnostics.
Methods
Study setting
The study took place in Cape Town, South Africa. Cape
Town has a high TB burden with 28,658 TB cases and
953 MDR-TB cases notified in 2011 and a TB case noti-
fication rate of 752/100,000 population. Free TB diag-
nostic services were provided at 142 primary health-care
(PHC) facilities offering two different service platforms.
Community Health Centres (CHC) were large, busy fa-
cilities treating acutely ill adults and most offered only
TB diagnostic services. Clinics tended to be smaller, fo-
cused on disease prevention and offered both TB diag-
nostic and treatment services. All TB tests were done at
a central laboratory that received daily specimens via
courier and recorded results in a networked, electronic
laboratory database. Rapid, on-site HIV-testing was rou-
tinely offered to presumptive TB cases.
In 2010, a smear, culture and LPA-based diagnostic algo-
rithm was used (Fig. 1) with LPA done on culture isolates
or clinical specimens of high MDR-TB-risk presumptive
cases (those with previous TB, an MDR-TB contact or
from a congregate setting). Doctors at the TB-hospital
reviewed case records and prescribed MDR-TB treatment
but patients could initiate treatment at PHC facilities.
From 2011–2013, Xpert was phased in, replacing
smear microscopy for all presumptive TB cases (Fig. 1).
Full decentralisation of treatment occurred from 2012
with doctors at PHC facilities initiating standardised
MDR-TB treatment without the need for prior case re-
view at the TB-hospital.
Sampling
Patients in this study were part of a PROVE-IT observa-
tional cohort in 10 high TB-burden PHC facilities se-
lected from a total of 29 that met the criteria of a TB
caseload of >350 in 2009. Health facility and patient
sampling details are provided in Fig. 2. We limited the
number of facilities in this study for logistic reasons and
purposively selected four of these facilities to ensure ra-
cial / ethnic representation and a socio-economic mix of
Naidoo et al. BMC Health Services Research  (2015) 15:488 Page 2 of 13
patients from both informal settlements and established
residential areas.
Eligible patients were >18-years of age, had been diag-
nosed with rifampicin or rifampicin and isoniazid resist-
ance from sputa taken and tested in Cape Town between
June 2010 and December 2012, and had received MDR-
TB treatment at one of the four PHC facilities. Patients
with previous MDR-TB treatment were excluded as their
pathway to care may have been different. Patients with
additional drug-resistance, in hospital or in prison, still
smear-positive or with loss to follow-up at the time of the
scheduled interview were excluded (Fig. 2).
Patients diagnosed at the selected facilities were identi-
fied from an electronic laboratory database; those diag-
nosed elsewhere, but on treatment at these facilities,
were identified through facility registers and clinical re-
cords. As patients in each diagnostic algorithm became
eligible, PHC facility nurses enquired whether they were
willing to participate and provided their contact details
to researchers for structured interviews. We purposively
sampled a subset from the four facilities for qualitative
interviews, stratifying participants by age, gender and
MDR-TB risk profiles. PHC facility nurses asked selected
patients if they were willing to participate in the second
interview. Recruitment continued until an appropriate
range of participants was interviewed and saturation was
achieved in terms of key findings in both algorithms and
no new themes appeared to emerge. We interviewed 16
patients diagnosed in the LPA-based algorithm between
2010 and 2012 and 10 patients diagnosed in the Xpert-
based algorithm between 2011 and 2012.
The research team
The research team comprised a senior social scientist with
oversight for this qualitative study (NL), two social science
field researchers, two professional nurses, a health sci-
ences researcher (MvN), a PhD medical researcher who
was the principal investigator (PN) and a clinician (EdT).
None of the researchers were involved in the delivery of
health services or care of patients.
Data collection
As part of the broader PROVE IT study, professional
nurses reviewed clinical records and completed a case
record form (CRF) with demographic and clinical infor-
mation. Three to six months after MDR-TB treatment
had commenced, field researchers contacted eligible pa-
tients, obtained informed consent, interviewed patients
and completed a structured questionnaire (Interview 1)
detailing the care-seeking pathway, health-care visits and
services received. Shortly thereafter, field researchers
contacted the patients selected for this study, took in-
formed consent again and conducted in-depth qualita-
tive interviews in English or the patient’s mother tongue
(Interview 2). We elected to use interviews to elicit pa-
tients’ first-hand experiences of their pathway to care.
For infection control purposes, interviewers and patients
wore N95-respirators and interviews were conducted in
Fig. 1 Testing in the LPA and Xpert-based TB diagnostic algorithms. High MDR-TB-risk presumptive cases refer to those with previous TB,
an MDR-TB contact or from a congregate setting. In the LPA-based algorithm, only these cases were initially screened for drug susceptibility. Low
MDR-risk presumptive TB cases would only be identified when 1st-line TB treatment regimens failed. In the Xpert-based algorithm in comparsion, all
presumptive TB cases were simultaneously screened for TB and rifampicn resistance using Xpert
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well-ventilated, private spaces at PHC facilities. Both the
CRF and structured questionnaire were reviewed prior
to interviews and the information was used to probe and
clarify responses provided by the patients.
A semi-structured interview guide with open-ended
questions was used. Patients were asked to provide a de-
tailed account of their experiences from symptom onset
to MDR-TB treatment initiation. Aspects of the care path-
way explored in detail included patients’ recognition of
their initial symptoms, their decisions around where they
sought medical care, their experience of these health ser-
vices and their MDR-TB diagnostic and treatment initi-
ation process. All interviews were digitally recorded,
translated into English where necessary and transcribed.
Data analysis
Data analysis was undertaken by three of the authors
(PN, MvN, NL). Each analyst read interview transcripts
several times during the course of the study to familiar-
ise themselves with their content. Analysts used open
coding to independently identify key issues and themes
in each stage of the care pathway with constant compari-
son within and between groups. We jointly recorded key
events and issues for each patient on a treatment journey
matrix based on data from the interview, supplemented
by data from the case report forms and structured ques-
tionnaires. Consensus was reached through discussion.
We used a combination of deductive (having explored
specific aspects of the care pathway and the motivation
behind patients’ actions) and inductive analysis, identifying
common and divergent themes emerging from the data
that were not specifically elicited [33].
Ethics
The City Health Directorate and Western Cape Health
Department granted permission to undertake the study.
Fig. 2 Primary health facility and MDR-TB patient selection. Patients in this study were part of a PROVE-IT observational cohort in 10 high TB-burden PHC
facilities selected from a total of 29 that met the criteria of a high TB caseload in 2009. The flowchart indicates the selection of health facilities and patients
for this study. Data from Interview 1 elicited quantitative information related to duration of illness, health-seeking visits and providers, cost incurred and
socio-economic status data (used for costing purposes, to evaluate delay and to supplement information on patient pathways). Interview 2
was an in-depth qualitative interview exploring patients’ perspectives of their pathways to care and formed the basis for this manuscript
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The Health Research Ethics Committee at Stellenbosch
University (IRB0005239) (N10/09/308) and Ethics Advis-
ory Group at The International Union Against Tubercu-
losis and Lung Disease (59/10) approved the study and
provided a waiver of informed consent for the use of
routine data. Written informed consent, in the patient’s
preferred language, was obtained prior to completion of
the structured questionnaire and qualitative interviews.
Patients were provided with refreshments but were not
reimbursed financially for interviews.
Results
We interviewed 12 female (6 in each group) and 14 male
participants ranging from 20 to 58 years in age. Thirteen
patients had previously been treated for TB and 17 were
co-infected with HIV.
We present key themes in four components of the
care-pathway: symptom recognition, health-care access,
testing for MDR-TB and MDR-TB treatment initiation.
We have combined the description of patients’ experi-
ences for both the LPA and Xpert-based algorithms and
have highlighted similarities and differences. We identi-
fied both enablers and barriers to early MDR-TB diagno-
sis and treatment and summarise these in Table 1.
Symptom recognition
Patients described their symptoms, what they attributed
these to and what led them to seek care. Most described
Table 1 Barriers and enablers in the pathway to early MDR-TB diagnosis and treatment initiation
Enablers Barriers
Symptom recognition •Symptom recognition based on history
of previous TB
•Failure to recognise TB symptoms
•Minimisation or denial of symptoms
•Social contact with TB/MDR-TB patients •Lack of awareness that TB can recur
•Awareness of increased risk of TB amongst
HIV-infected patients
•Incorrectly ascribing symptoms to
HIV or other medical condition
Accessing health-care •Perceptions of good quality service •Negative perceptions of the public sector (over-burdened;
long waiting times; negative staff attitudes; lack of privacy)
•Convenience of free, accessible local services.
•Familiarity with service
•Family support •Fear of an HIV diagnosis
•Responsiveness of provider at first health contact •Social construct of “being aman”, not admitting illness (seen as weakness)
MDR-TB Testing •Attendance at facilities geared towards TB
(i.e. offering both TB diagnosis and treatment)
•Entry point to care through the private sector
•Availability of Xpert MTB/RIF •Accessing facilities providing TB diagnostic but not treatment services.
•Screening of all presumptive TB cases for
drug resistance
•Health providers failure to test for TB / MDR-TB at initial health contact
•Patient’s agency in specifically requesting TB
screening services that were not offered
•Health providers’ failure to follow diagnostic algorithms
•Patient’s agency in pursuing diagnostic
processes after initial negative tests
•Interruptions to the diagnostic process due to dissatisfaction
with the service, work and family commitments
•Lack of money for transport to return to facility
•Insensitive tests that fail to diagnose TB
•Patients diagnosed clinically or on chest x-ray
and started on 1st-line TB treatment
•Failure to respond early to clinical deterioration
for patients on 1st-line TB treatment
Initiating MDR-TB
Treatment
•Health provider scheduling early
return visits for MDR-TB test results
•Patients failure to return for follow-up appointments
•Patients returning for
scheduled appointments
•Delays in recalling patients
•Availability of decentralised
MDR-TB treatment
•Results not being available at follow-up appointments
•Perceptions that staff cared about
their patient’s well-being
•Family commitments preventing a return to facilities
•Cultural beliefs and seeking traditional
healthcare (often in another province)
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symptoms typically associated with TB such as cough,
night sweats, loss of appetite, weight loss, fever, chest
pain and general malaise. Some, particularly those with
HIV, described symptoms related to their co-morbidity
as their primary concern, for example painful feet for a
patient on antiretroviral treatment.
The role of previous TB treatment or social contact with TB
patients
Half the patients had previously been treated for TB and
many recognised their symptoms as a recurrence. Sev-
eral responded by quickly seeking help at a PHC facility
as this patient explained: “I had all the symptoms that I
had the last time when I had TB. So I wanted them to
check [for TB]” (Xpert-4). Having had TB before did not
always mean that patients recognised recurring symp-
toms or sought timely help. One patient explained: “I
did not believe it could be TB again because I completed
my treatment the first time” (Xpert-9). Several patients
reported that contact with someone on TB or MDR-TB
treatment heightened awareness of their symptoms: “I
thought I had TB because I stayed with someone who
had TB and he did not take his treatment” (LPA-15).
Another explained: “I did not know much about MDR-
TB. My [relative] had MDR-TB and told me to check if I
don’t have it” (Xpert-7).
The interaction with HIV
For some HIV-infected patients, awareness of their in-
creased risk of TB motivated their response: “I was
coughing, my bones pained and I was losing weight…I
thought I had TB …I went to the ARV doctor because I
had an appointment … and told him how I feel. I asked
him to send me for a TB test” (LPA-15). However other
HIV-infected patients incorrectly ascribed their symp-
toms to HIV and delayed seeking care. Fear of being di-
agnosed with HIV presented a barrier to accessing early
care as one patient explained “My mother said I must go
to the clinic for a TB test. She was worried that I may
have TB because my [relative] also had TB. I did not
want to go …too scared that if I go for a TB test they will
also test me for HIV” (LPA-2).
Failure to recognise or acknowledge TB symptoms
Patients who did not recognise symptoms as TB–related,
tended to minimise their significance. Several attributed
symptoms to other factors, including smoking tobacco
and the weather: “I was having a terrible cough and I
was sweating at night, but this did not ring an alarm for
me, because I still thought this was just a fever and the
change of season and that everything was going to be
fine” (LPA-3). Others mistook symptoms for “flu”,
asthma or other medical conditions: “My grandfather
had TB in 2006. I knew the symptoms of TB are when a
person is coughing and getting very thin…I did not think
about TB… I thought it was swine flu…Everyone was
talking about swine flu” (LPA-16).
Some patient’s minimised their symptoms to avoid
causing undue worry to their family. Family roles and re-
sponsibilities and the expectations that come with these
contributed, as one patient reported: “at the time when I
started to feel sick I felt that I had to act a little bit
strong, to not let the family know how weak I really felt. I
must not let them down. Although I could feel some pain
I felt I must be a man to face this disease” (Xpert-7).
Patients tended to show considerable tolerance for
their symptoms, referring to these as “just a cough” or
“just losing weight”. A patient who completely dismissed
his symptoms said: “But at all these times I was not sick.
It was just a cough, sweat at night and I felt that I was
also losing weight, nothing else, not a day I ever felt like I
was sick” (LPA-8). Symptom tolerance or denial resulted
in some patients presenting for care when they were ex-
tremely ill, having lost substantial weight or being too ill
to walk.
There was wide variation in the time from symptom
onset to seeking health-care. Some, especially those who
recognised they may have TB, took early action. Others
delayed seeking care, sometimes for several months, until
their symptoms were much worse. The stigma of possibly
having TB did not emerge as an issue influencing patients’
actions. The findings on symptom recognition were simi-
lar for patients in both the LPA and Xpert-based algo-
rithms. It was interesting to note that none of the patients
in the Xpert group reported a heightened awareness of TB
or of the newly introduced test.
Accessing health-care
Patients described when and where they first sought care
and what motivated their choice of provider. Although the
public sector was the most common entry-point to care,
several (about one third) first visited the private sector.
Public sector as the entry-point to care
Convenience, accessibility, familiarity with the services
and cost were the commonest reasons for patients
choosing the public health sector. Patients accessed and
moved between CHCs and clinics and experiences dif-
fered between these. Several patients who first attended
a CHC were treated with antibiotics for an acute chest
infection and were not initially screened for TB; in com-
parison, most patients attending clinics were initially
screened for TB, although not necessarily for MDR-TB.
Previously treated patients tended to return to their
local clinic for care due to familiarity and satisfaction
with the previous service: “I had TB before and knew the
symptoms of TB. I decided to go to the clinic where I stay…I
was very satisfied with the treatment that I got [previously]”
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(Xpert-7). Several patients chose to go to the clinic or CHC
providing their antiretroviral treatment and requested TB
tests at scheduled appointments; others were screened dur-
ing antiretroviral treatment re-initiation.
A few patients specifically chose a CHC, because of
the services offered, including emergency services and
the availability of chest x-rays. A patient who attended
for these reasons commented: “I was very worried because
I could not walk. I thought something serious is wrong with
me. My [friend] called the ambulance” (LPA-10). Like
other patients who had attended a CHC, this patient com-
mented on the difficulties in accessing care: “[the CHC]
was very full. I don’t like [the CHC] and would not like to
go there again… Lots of chaos. The nurses rushed me, they
don’t give me time to talk and explain what’s wrong with
me. This is not right for me. They don’t care about the pa-
tient. Once I was there and the nurses just went on tea,
even if the very sick people are waiting on them. I told the
nurse about a sick, old man and she said “he must just
wait”. They just don’t care about the patients” (LPA-10).
Although long waiting times were a common com-
plaint, a few accepted this status quo: “I waited for a long
time before I was attended, but I understand that is the
way it is. There are lots of people that need to be
attended to everyday here at the clinic. But I knew that
at the end of the day I was going to get assisted. I just
told myself that… I am sick already and I need help and
in order for me to get help I must be patient” (LPA-5).
In contrast, some patients reported positive experiences:
“…I was sure I was going to stand in a long queue, but I ex-
plained to the TB nurse what was wrong with me and
without me standing in a queue she told me to go to the
TB room” (LPA-8). Another explained “I was expecting
long queues and sitting for ages before getting help. I am
not sure what the situation is at the other clinics, but …
there was no queue and I got helped within 10 min…Staff
in the TB room is very helpful and treats the patients with
respect” (Xpert-9).
Private sector as the entry-point to care
Several patients first visited the private sector, most
commonly general practitioners (GP), due to perceptions
of better services. They perceived the public sector to be
over-burdened, with long waiting times, negative staff at-
titudes and a lack of privacy. Waiting times, in particu-
lar, were considered a barrier: “I don’t like coming to the
clinic when I’m not feeling well…You wait for a long time
before they can attend to you…At the doctors room the
treatment and waiting time was very reasonable. I only
had to wait for 20 min. Here at the clinic, you wait…you
can wait for 8 hours here” (LPA-4).
Having financial resources enabled patients to visit a
GP; however, in some cases, they did not return as rec-
ommended due to financial constraints. Reflecting on
their management in the private sector, several patients
felt that visiting a GP had been a waste of time and
money. One patient had the following advice for those
with TB symptoms: “I can advise them all to go to the
clinic…. There are much better options at the clinic than
the private doctors…lots of test which can be taken…lots
of tests which will find out what is wrong with you….For
someone to get those things you have to be patient
though” (LPA-6).
Patients that first sought help at a pharmacy often
underestimated the seriousness of their symptoms, as-
sumed these were self-limiting and self-medicated with
cough mixtures.
We found no significant differences between the LPA
and Xpert-based algorithms in the point of first health-
care access or in patients’ experiences. Despite perceptions
of long waiting times, lack of privacy and poor staff atti-
tudes, most patients reported that they would recommend
that family and friends with TB symptoms go directly to
PHC facilities, to reduce the cost and time to diagnosis.
Testing for MDR-TB
Patients described how they came to be diagnosed with
MDR-TB; the steps involved and the time it took. With
the exception of two patients, most experienced lengthy
delays due to providers not testing for TB or MDR-TB
at initial visits, failure in the testing technology and
patient-related delays, including interruptions to the
diagnostic process and missed follow-up appointments.
Delays due to the first health provider not testing for TB
None of the patients who initially visited a pharmacy
were referred for TB tests; a few subsequently visited a
general practitioner, before eventually being investigated
for TB at their local PHC facility. This contributed to
MDR-TB diagnostic delays. In one extreme example, a
patient with persistent cough described visits to the
same pharmacy over a 6-month period: “I went back
again and again to the pharmacy and got different medi-
cation every time. I must have gone there five times”
(LPA-13).
Most patients who visited general practitioners were
diagnosed with acute respiratory infections and treated
with antibiotics, without TB investigations. Some had
chest x-rays taken and a few had sputum tests. Some pa-
tients who did not respond to initial treatment had early
referral to PHC facilities; others who could not afford to
continue with private sector care attended the public
sector when their health deteriorated. Several patients
who visited general practitioners experienced lengthy de-
lays as a result of numerous visits and courses of antibi-
otics, before seeking or being referred to a PHC facility
for investigation.
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In the public sector too, particularly at CHCs, some
patients with a chronic cough were treated with several
courses of antibiotics before a TB test was done. After
an initial general practitioner visit one patient reported:
“I was at [the CHC] for 24 hours in December …they told
me that I had infection in my lungs and gave me the drip
and antibiotics…In the same month I didn’t feel so well
so I went back… and they gave me the same drip and
antibiotics” (LPA-16).
In the most extreme example of missed diagnostic op-
portunities a young woman was started on MDR-TB
treatment 15 months after first seeking health-care. Des-
pite repeated visits to both the private and public sector,
the patient was not adequately evaluated for TB, includ-
ing during pregnancy. She was diagnosed several months
after her baby’s birth with serious consequences includ-
ing her baby contracting MDR-TB (see Fig. 3).
Delays due to the first health provider not testing for drug
susceptibility
In the LPA-based algorithm, low MDR-TB risk patients
did not have initial drug susceptibility tests (DST); this was
done only when 1st-line TB treatment failed, resulting in
substantial delays to MDR-TB treatment. In comparison,
in the Xpert-based algorithm, all presumptive TB cases
were required to have an Xpert test and were concurrently
evaluated for tuberculosis and rifampicin resistance, theor-
etically reducing these delays. In both algorithms however,
there were many instances where the correct tests were
not initially done, contributing to diagnostic delays.
Fig. 3 Delayed access to treatment - in their own words
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Patients who experienced delays commented on the dis-
tress they felt whilst on 1st-line TB treatment. For one pa-
tient, diagnosed on smear microscopy by a general
practitioner and referred to a PHC facility, a series of
health service failures contributed to delay. The patient
was at high MDR-TB-risk and despite the clinician request-
ing an Xpert test, only smear microscopy was done and the
patient was started on 1st-line TB treatment. Nurses did
not respond to the patient’s complaint of worsening symp-
toms. After sputa were taken to evaluate response to treat-
ment the patient reported: “When the results came back
they told me I do not take my tablets. I told them ‘but I take
my pills every day’. They could not understand why my re-
sults were 3-plus positive. I told them ‘my [spouse] sees
when I take my tablets in the morning’. This made me very
troublesome… In all the time that I took the treatment I felt
the same. The treatment did not help….I started to give up
hope” (Xpert-6). The patient started MDR-TB treatment al-
most 5-months after initial tests; following routine screen-
ing the patient’s child was also diagnosed with MDR-TB.
Delays due to initial negative or invalid tests
Patients in both algorithms were sometimes diagnosed
on chest x-ray after negative initial smear or Xpert tests
and commenced on 1st-line TB treatment as this patient
explained: “So finally after three days the results came
back.… and a few days later they said I was negative,
but I was still getting sicker.” (Xpert-8). This patient per-
sisted, seeking care from another facility: “I went to [the
CHC] again like someone who does not know what’s
wrong with them. I told the doctor ‘I already gave spu-
tum’ and I went for x-rays and that’s when she saw the
x-ray and sent me straight here and they … put me on
treatment”. As per policy, this HIV-negative patient did
not have an initial sputum culture test; this was only
done two months after 1st-line TB treatment was started,
contributing to a 4-month delay in MDR-TB treatment.
In comparison, a patient who was investigated for TB
shortly after commencing antiretroviral treatment re-
ported: “I gave in the sputum and came back to the clinic
after 3 days. The result was negative…I went again to the
ARV clinic and they sent me for chest x-ray .My chest x-
ray was also negative….I went back to work. [One day] I
was preparing to go to work. My phone rang and it was
the clinic that said I must come to them immediately”
(Xpert-5). The patient was diagnosed on a culture test,
resulting in a 6-week delay to MDR-TB treatment.
Patients’ roles
Patient narratives presented several examples of their
agency in persisting with the diagnostic process when
symptoms did not resolve and in requesting tests that
should have been offered but were not. One patient ex-
plained: “I knew I was HIV positive, and that made me
more worried when I felt sick. Even when my TB results
were negative…I went again for a TB test” (LPA-14).
Whilst not playing a major role, patient factors contrib-
uted to delays during the diagnostic process due, for ex-
ample, to work and family commitments and being
unable to pay for transport to return to facilities.
A comparison between the LPA and Xpert-based Algorithms
There were many examples of remarkably similar pa-
tients’ experiences between the LPA and Xpert-based al-
gorithms, with a 1–2 month delay between submitting
the MDR-TB test sputum and treatment initiation. De-
lays overall were longer for patients in whom initial tests
were negative with 1st-line TB treatment started on clin-
ical or chest x-ray findings.
With Xpert, there were two examples of rapid MDR-
TB diagnosis where a test submitted at the first health
contact diagnosed rifampicin resistance (see Fig. 4). A
patient elucidated: “At the clinic I was given the bottle to
give sputum… After that I was given a follow-up date to
come the following week for my results, and when I came
back I was told that it looks like I have TB and that this
TB is not like the first one…. I was told that I needed to
see the doctor because I have a “big TB, MDR-TB” a
more serious TB, not the normal one” (Xpert-2).
MDR-TB treatment initiation
Patients described their experiences of receiving test re-
sults and initiating treatment. We identified both health
system and patient factors contributing to delays.
Health system factors contributing to delay
Problems were experienced with facilities failing to re-
ceive laboratory results, resulting in multiple return
trips, as one patient explained: “After returning for my
results and waiting for a long time, I was told that I
needed to come back again after two days. After another
two days I was told my results were not received due to a
broken fax machine. After this day I decided not to come
back because I was waiting too long in the queue for my
results and I was feeling better at this stage” (LPA-5).
Once the PHC facility received the MDR-TB test re-
sult, there were delays in recalling patients, although
from patient accounts, the reasons for this were not al-
ways clear. Several patients indicated that a health
worker was able to contact them telephonically or visited
their home. Some indicated that the PHC facility struggled
to contact them initially, for instance, when messages were
not relayed to them. Substantial delays occurred in recal-
ling some patients. One patient who tested smear-negative
in April and went to visit family in another province to re-
cuperate reported: “In mid-August the ..clinic phoned me to
check when I will be back home. They did not say why. I
only went back at the .end of August and was informed…
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that I have MDR-TB. This was another shock for me. I was
very disturbed that the clinic [had] not told me this while I
was [away]. I was living unaware of this very contagious
disease…I think this was very irresponsible of the clinic. I
told them… when they explained the seriousness of MDR-
TB to me….I was a danger to my family and could have
been on treatment 2-weeks earlier“ (Xpert-9). In this ex-
treme example, the patient was not aware that her results
were in fact available three months prior to the patient be-
ing contacted.
Patient factors contributing to delay
Delays occurred when patients failed to return for
scheduled appointments and had to be recalled. For a
few, seeking traditional health-care at their family home
in another province contributed to delays, as did family
commitments. One patient explained: “The day..I was
told I have MDR-TB, my family phoned…with the news
that my sister passed away. Everything then went crazy.
All I could think about then was the fastest way to get
[home.] I am the eldest son and must make all the prep-
aration and decisions for the funeral. I left very early the
next morning…not thinking about my MDR-TB treat-
ment, maybe because my mind was very occupied with
my family responsibilities and also because I did not feel
that sick” (LPA-12).
The impact of an MDR-TB diagnosis
Patients spoke at length about the range of emotions they
experienced on receiving an MDR-TB diagnosis. Although
devastating for most patients, the diagnosis was often ac-
companied by a sense of relief at finally knowing what was
wrong with them. For many experiencing financial and
other hardships, diagnostic delays exacerbated their diffi-
culties. There were also feelings of guilt about infecting
others, especially children: “ it hurts me a lot, I don’t even
want to go there, I am feeling very bad, very, very bad, be-
cause if this was detected earlier I was not going to go
through some difficulties that I went through. You know…
when I think that I even infected my child it makes me feel
very bad. Because if this was detected early and [I was]
started on the right treatment, maybe some of the problems
would have been eliminated” (LPA-3). Overall, six children
in the households of the 26 patients interviewed were di-
agnosed with MDR-TB.
Discussion
Limited data are available on the impact of new molecu-
lar diagnostic tests on MDR-TB patients. Two studies
Fig. 4 Expedited access to treatment - in their own words
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comparing conventional DST to LPA showed reductions
in median treatment commencement times from 72 to
24 days [6] and 80 to 55 days [7] respectively. The
PROVE-IT evaluation found a reduction from 43 days in
the LPA-based algorithm to 17 days in the Xpert-based
algorithm [8]. These findings however provide a limited
view, excluding the period prior to MDR-TB tests being
taken and do not explain, for example, why it takes
17 days to get a patient onto treatment despite a labora-
tory turn-around time of <1 day [8]. There is a paucity
of literature detailing patients’ experiences of MDR-TB
diagnosis and treatment initiation and this is one of the
few studies to report specifically on this.
Our findings show that patients’ pathways to MDR-TB
care varied: some were expedited, with treatment initiated
within a week of first health provider contact, thus achiev-
ing the anticipated benefit of Xpert. However obstacles at
all stages in the pathway delayed treatment for many pa-
tients in both the LPA and Xpert-based algorithms. Some
of these delays could be considered as unavoidable (per-
haps due to the complexity of the disease and the limita-
tions of tests), but some, especially those related to health
service failures, are clearly avoidable. We reflect on the
implications of these findings for reducing delays in the
pathway to MDR-TB treatment initiation.
Symptom recognition
We found no differences in patients’ recognition of their
symptoms in the LPA and Xpert-based algorithms. The
media coverage during the launch of Xpert in South Africa
did not appear to impact on patient’s health-seeking behav-
iour. Instead, factors that contributed to early symptom
recognition and health-seeking in both algorithms included
a previous history of TB, social contact with someone on
treatment (both of which are unhelpful from a public
health perspective) and awareness amongst some co-
infected with HIV of their increased risk of TB. However,
many patients deferred health-seeking for lengthy periods
of time. As was found in other studies, some waited to see
if symptoms like cough resolved spontaneously or im-
proved with self-medication [11, 13, 14]; others deferred for
fear of an HIV diagnosis [11–13] and patients who were
uncertain of the cause of their illness delayed health-
seeking or visited multiple providers [13–15]. The extent to
which patients deferred health-seeking is difficult to ascer-
tain bearing in mind the tendency to tolerate, underplay or
deny TB symptoms. This is likely to be a significant issue in
our setting, considering the chronic nature of TB and how
ill many patients were at their first health contact.
Studies have reported equivocal findings on the role of
TB knowledge in treatment delay [10,19, 20], with some
finding an association between poor knowledge and
delay [21–24] and others not [15, 25]. Our findings sug-
gest that knowledge about symptoms and perceptions of
risk influenced health-seeking. Raising awareness of TB
symptoms and the need to seek early care may contrib-
ute to reducing patient delays. Perhaps the heightened
awareness amongst those with previous TB presents an
opportunity: these individuals could be targeted by educa-
tion programmes to assume the role of “cough advocates”
in their communities, with benefits for their own health
too, as they are at higher risk of re-infection [26, 27]. The
introduction of a new test like Xpert presents an oppor-
tunity to influence health-seeking behaviour through
awareness campaigns that increase demand for the test.
Health-care access
About one third of the patients in our study first sought
care in the private sector, due to perceptions of poor
treatment in the public sector, particularly long waiting
times and poor staff attitudes. Poor TB screening prac-
tices in the private sector contributed to delays for many
patients. Other studies have also found that visits to pri-
vate providers and facilities not equipped to diagnose and
treat TB contributed to delays [13, 14, 19, 22, 28, 29]. Per-
ceptions of poor public sector services are frequently cited
as contributing to delay [11, 13–15] and may have con-
tributed both to deferred health-seeking and to patient’s
choice of the private sector in our study. Avoidance of free
public sector services calls for serious reflection on how to
improve service delivery. Improved TB screening practices
in the private sector and early referral to the public sector
are required to help reduce delays.
It is important to note that despite widespread negative
perceptions of the public sector, several patients reported
positive experiences at their first contact and almost all re-
ported positive experiences once on treatment and indi-
cated that they would recommend these services to family
and friends. We do not feel that conducting the interviews
at the health facilities influenced this sentiment as patients
spoke candidly about negative experiences. Efforts to im-
prove public health services could build on the positive
sentiments expressed by patients.
Testing for MDR-TB and treatment initiation
Despite most patients, including those who were HIV-
infected, presenting with symptoms typical of TB, one of
the commonest factors contributing to delay in both diag-
nostic algorithms was health provider’s failure to test for
TB at initial contact. This occurred most frequently when
patients visited pharmacies, general practitioners and facil-
ities not providing TB treatment. Large population-based
surveys of health-seeking behaviour in other countries re-
ported similar findings: the majority with chronic cough
presented for care [23, 25, 30, 31] but only a small percent-
age were evaluated for TB [30, 31]. Efforts need to be
made to increase the “index of suspicion” of TB amongst
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both private and public sector providers, especially those
not providing TB treatment, to ensure appropriate testing.
An advantage of the Xpert-based algorithm is that by
targeting all presumptive TB cases and not only those at
high MDR-TB risk, it should diminish the problem of
patients with primary MDR-TB being placed on 1st-line
TB treatment and the ensuing suffering that patients de-
scribed as their health deteriorated.
The potential of an Xpert-based algorithm to substan-
tially reduce delay is highlighted by two examples of
rapid initiation of MDR-TB treatment, within 6 and
8 days of the first health contact, respectively. Early ac-
cess to treatment was enabled by the correct tests being
requested which yielded a positive result, results being
available when patients returned and decentralised treat-
ment being available. In comparison, the earliest access
for three patients in the LPA-based algorithm was within
31–38 days of the first health contact, reflecting the time
taken for a culture and DST result with LPA.
However, more often than not, health system factors
including failure to adhere to testing algorithms, prob-
lems with receiving the results, scheduling follow-up
visits and recalling patients with positive results, all con-
tributed to substantial delays. The introduction of rapid
diagnostics therefore needs to be coupled with measures
that address these structural barriers and minimize
organizational delay [20, 32]. Patient-related delays (due
to missed follow-up appointments, competing family de-
mands and seeking traditional health-care) contributed
to a lesser extent.
Our findings highlight not only the factors influencing
the pathway to MDR-TB treatment, but also the impact
on the lives of patients. Patients described how their
physical and emotional suffering during the long and
sometimes, tortuous pathway to treatment initiation
compounded already difficult socio-economic and family
circumstances. For some, the impact on their families
was experienced as devastating, in particular, when chil-
dren were infected. There was recognition (and anger)
amongst some, that reducing diagnostic delays may have
averted some of these infections.
Limitations and strengths
The study has limitations. It was undertaken in Cape
Town which is urban, relatively well resourced and with
decentralized MDR-TB care. Obstacles to care may be
greater in poorly resourced areas, in rural settings and
with centralized care. The study does not reflect the ex-
perience of the sickest MDR-TB patients (those in hospital
or still smear positive), those not initiating MDR-TB treat-
ment and those who were lost to follow-up, and may
therefore present a more optimistic view of pathways to
care. One of the major strengths of this study is that we
were able to increase the validity of patient reports by
triangulating data from interviews with clinical informa-
tion and data from a structured questionnaire on health
visits and services received. This also provided important
context to patient’s narratives and deepened our under-
standing of pathways to care. Whilst the small sample in-
cluded in the study may not have been statistically
representative of all MDR-TB patients, we felt that we had
captured an adequate range of experiences. Qualitative re-
search, where patients are required to convey their experi-
ences and the meaning they attribute to these [33]
contributes important evidence on the impact of molecu-
lar diagnostic tests.
Conclusion
The history of TB control efforts around the world has
shown that having the right technology will not by itself
resolve complex medical and public health challenges
[34, 35]. We are likely to confront a range of barriers in
making the most of new diagnostic technologies [36].
Whilst the introduction of Xpert clearly has the poten-
tial to reduce MDR-TB diagnostic and treatment delays,
this alone does not suffice. Addressing patient delays in
health-seeking is important. However, unless the struc-
tural barriers to care (correct evaluation at the first
health contact, appropriate referral between sectors, de-
veloping patient-friendly health systems that are better
organised to access results and commence treatment)
are also addressed, the potential of rapid molecular diag-
nostic tests such as Xpert are unlikely to be fully rea-
lised. We hope that patients’ perspectives will be a call
to action to address the obstacles identified in the path-
way to MDR-TB treatment initiation.
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